More effective treatments are currently required to help target the PIK3CA-mutant patient populations - one strategy that has been suggested is to exploit tumour metabolic dependency11, 12 by discriminating the metabolic regulation of the various oncogenic mutations. The gene discussed is PIK3CA; the disease is neoplasm.